

minutes  
indment  
26-04

Claim 16 (currently amended): A method for the ~~prevention or treatment of T cell mediated diseases, or medical conditions in a warm-blooded animal in need of such treatment~~ which comprises administering to said animal an effective amount of a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, according to claim 1 ~~but without the proviso that the group of formula Ie so formed is not a purine ring and including the compounds:-~~

~~1-(6,7-dimethoxyquinazolin-4-yl)-3-phenylurea,~~  
~~1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-phenylurea,~~  
~~1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-bromophenyl)urea,~~  
~~1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-methoxyphenyl)urea,~~  
~~1-phenyl-3-(pyrazolo[3,4-d]pyrimidin-4-yl)urea,~~  
~~1-(2-chlorophenyl)-3-(pyrazolo[3,4-d]pyrimidin-4-yl)urea,~~  
~~1-(3-chlorophenyl)-3-(pyrazolo[3,4-d]pyrimidin-4-yl)urea,~~  
~~1-(4-chlorophenyl)-3-(pyrazolo[3,4-d]pyrimidin-4-yl)urea,~~  
~~1-(2-fluorophenyl)-3-(pyrazolo[3,4-d]pyrimidin-4-yl)urea,~~  
~~1-benzyl-3-(pyrazolo[3,4-d]pyrimidin-4-yl)urea and~~  
~~1-(3-phenylpropyl)-3-(pyrazolo[3,4-d]pyrimidin-4-yl)urea.~~